Russian pharmaceutical producer Polysan will invest about RUB4bn ($60m) in the full-cycle production of German drug firm Bayer's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 2015 on the production of Gadovist, Magnevist and Ultravist at Polysan's St Petersburg facility. Bayer said it would use its existing facilities for manufacturing Xarelto, which is used as a treatment against blood clots caused by high levels of fibrinogen (a protein that binds with iron to
Russian pharmaceutical producer Polysan will invest about RUB4bn ($60m) in the full-cycle production of German drug firm Bayer's anticoagulant Xarelto (rivaroxaban). The two companies previously partnered in 2015 on the production of Gadovist, Magnevist and Ultravist at Polysan's St Petersburg facility. The latest collaboration will also see Polysan's antiviral treatment Cytoflavin manufactured at the plant.